Henan Taloph Pharmaceutical StockLtd Management
Management criteria checks 1/4
We currently do not have sufficient information about the CEO.
Key information
Jingliang Li
Chief executive officer
CN¥1.2m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 1.5yrs |
| CEO ownership | n/a |
| Management average tenure | no data |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
The Market Doesn't Like What It Sees From Henan Taloph Pharmaceutical Stock Co.,Ltd's (SHSE:600222) Revenues Yet
Sep 27
Henan Taloph Pharmaceutical StockLtd (SHSE:600222) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 06Henan Taloph Pharmaceutical Stock Co.,Ltd (SHSE:600222) Surges 26% Yet Its Low P/S Is No Reason For Excitement
Mar 08CEO
Jingliang Li (55 yo)
1.5yrs
Tenure
CN¥1,170,500
Compensation
Mr. Jingliang Li serves as Vice Chairman of Henan Taloph Pharmaceutical Stock Co.,Ltd., since February 25, 2022 and serves as its General Manager since June 25, 2023. He served as Chairman of Directorate a...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| GM & Vice Chairman | 2.8yrs | CN¥1.17m | no data | |
| Independent Director | 5.3yrs | no data | no data | |
| Director | 1.5yrs | CN¥849.60k | no data | |
| Independent Director | 3.3yrs | CN¥100.00k | no data | |
| Chairman | 2.8yrs | no data | no data |
2.8yrs
Average Tenure
59yo
Average Age
Experienced Board: 600222's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 16:14 |
| End of Day Share Price | 2024/12/25 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Henan Taloph Pharmaceutical Stock Co.,Ltd is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Min Luo | Central China Securities Co., Ltd. |
| Wen Liang Cui | Founder Securities Co., Ltd. |
| Xiao Feng Wang | Shenwan Hongyuan Securities |